Phase 1 Clinical Trials of DAS181, an Inhaled Sialidase, in Healthy Adults

DAS181, (study drug, Fludase®) was developed for treatment of influenza and parainfluenza infections. Delivered by inhalation, DAS181 cleaves sialic acid receptors from respiratory epithelial cells. Treatment of influenza for three days with DAS181 reduced viral shedding. To increase deposition in t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antiviral Res
Main Authors: Zenilman, Jonathan M., Fuchs, Edward J., Hendrix, Craig W., Radebaugh, Christine, Jurao, Robert, Nayak, Seema U., Hamilton, Robert G., Griffiss, J. McLeod
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639451/
https://ncbi.nlm.nih.gov/pubmed/26391974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2015.09.008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados